Get started

PHARMA

Biogen Earnings Swing July 2018Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was certainly reason for bullish sentiment, it ran too far too fast and indicators pointed towards to a sell off. I thus opened put options on July 9, expiring July 13 2018 (currently in the money). We are now only about two weeks away from Biogen's earning report. After studying historical data and charts, I've found that there is often a sell off prior to earnings OR there is a run up then a slight sell off right before the earnings date. I've annotated the chart with periods that indicate this. In this case, I believe downward momentum will continue followed by a slight rally pre-earnings then a sell off. Opening JUL20 puts may be a smart move at this time. In the long term, Biogen -0.21% is very scalable and overall is very promising. I agree with Citi's PT of 371. www.wsj.com
NASDAQ:BIIBShort
by UnknownUnicorn2997486
ATNX to retest Support high 17's to mid 18'sATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset. ***Any information represented here is my opinion only and not intended to be used for financial gain. None of the information posted here is to be considered financial advice. Information posted here is strictly for entertainment purposes only. Please consult your financial professional before making any kind of investment. Investments can be very risky and any investor should educate themselves before investing by enlisting the help of a financial professional. Past results are not indicative of future results in any construable way.***
A
by algocowboy2030
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised this week: fortune.com markets.businessinsider.com finance.yahoo.com Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol. www.streetinsider.com -new form of asthma inhalation treatment -breath actuated I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
NYSE:TEVA
by UnknownUnicorn2421992
1
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
SLong
by ArthaVidya
1
Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds. Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good. Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2. Low free float in the stock ( 60% in hands of major shareholders ). Major funds holding ( Woodford Investment Management and Lansdowne Partners ). High profile investors holding stakes ( Richard Griffiths and Leonard Licht ). These high profile investors have been raising, rather than reducing their stakes in the company, periodically. For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
LSE:SNGLong
by richthenewbie
3
ASX Star Combo Pharma Star Combo Pharma has just started trading last week. It has a good run up to above $2. I believe this is Wave 1 of Elliot. The price has dropped a bit at writing and if I am not wrong, corrective wave 2 will probably hit between 0.5 to 0.618 in the next few days. If i were to trade, i would look for entry below $1.30 between 0.5 to 0.618 fibonacci. At writing, there was a bounce at 0.384 fib @ about $1.40. If my charts are correct, we are looking at corrective wave B of 2 then C down to 0.618 fib. We shall see. ABOUT THE COMPANY --- extracted from: www.afr.com A company that acquired the Living Healthy vitamins and health supplements brand from pharmacy chain Terry White Chemmart last year wants to make a big shift from being a contract manufacturer to launching its own brand. Star Combo Pharma has raised $7 million in an initial public offering at an issue price of 50¢, and will list on the ASX on Wednesday, with chairman Richard Allely outlining ambitious growth plans. The company signed a three-year distribution deal with Terry White Chemmart as part of the acquisition where the Living Healthy vitamins brand will be on the shelves of 450 of the group's pharmacies. Mr Allely said Star Combo currently generated about 70 per cent of its revenues through contract manufacturing for other vitamins companies in western Sydney. About 30 per cent of its revenues come from its own brands, which include Costar, Amax and J&K. Those three brands are largely sold in gift stores and duty free stores. The Living Healthy brand had undergone a rebadging and repackaging, and Star Combo was aiming to accelerate its growth. Between 20 and 30 individual product lines, known as stock-keeping units, would be on the shelves of Terry White Chemmart outlets around Australia. Star Combo was also eyeing a big push into China, to try to emulate in a smaller way the success of big players such as Blackmores and Swisse. At the issue price of 50¢, Star Combo has an indicative market capitalisation of $38 million. Mr Allely said the IPO had been oversubscribed and the company had been forced to scale back applications. The company made a net profit of $1.48 million in 2016-17 from revenues of $9.84 million. Net profit in 2015-16 was $1.59 million from revenues of $9.4 million.
SLong
by paper_value
CELG Q1 2018 Earnings on 5/4 - Are Traders Rotating In or Out?What a tumultuous market. Celgene reports earnings on 5/4. Earnings play aside, are traders and investors rotating into or out of pharmaceuticals? The market doesn't know what to do with itself right now. With a Fed meeting taking place over the next couple days, Caterpillar's CFO claiming we've seen a "high water mark" with Q1 earnings, rate concerns, trade concerns, and historic geopolitical uncertainty (especially regarding Iran's nuclear program), some traders claim we've already seen April and May's strongly anticipated earnings rally. If that's true, 1. what a squishy rally, and 2. where do we go from here? Thanks in advance for lending me your attention! Pharmaceuticals are a wild card among the classical winners (usually, financials, materials, and energy) and losers (REITs, utilities, etc.) in a late-cycle rotation. It can be argued a lot of Wall Street cash has sought the arguably greener pastures of cryptocurrencies. But could we see prices move upward along the right side of the chart in pharmaceutical companies? CELG reports earnings on 5/4. Celgene took a dive on 4/30 on troubling news about a drug in its development pipeline. Did that drop make Celgene a bargain buy? CELG's drop on bad news has put it at technical support. The uncertainty of its earnings report and the market overall has it arguably priced cheap. Is Celgene a cheap buy in this market with a possible earnings surprise on 5/4 and upside potential with a rotation into pharma? Please like, follow, and share, and maybe we can have fun and do great things together. Thanks again! See it on the site: holsturr.com/category/markets/charts/ ** For speculative and research purposes only - good luck! **
CLong
by holsturr
SNSS short based on BB and RSIMY OPINION: Jumped into SNSS at this low signal of 4.24. This drop in share price occurred after recent earnings report on March 8th. This is a psychological pitfall, expecting shares to jump back between the middle and bottom Bands by mid week. THE FACTS: The company reported $0.21 earnings per share for the quarter Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $7.69. Among 5 analysts covering Sunesis Pharmaceuticals, 2 have Buy rating, 1 Sell and 2 Hold.
SShort
by SoWaVvY
CPHI Win or Fail? (Fib with RSI and Ghost bars)Lets see what next week will bring! After a recent check, the 14-day RSIfor China Pharma Holdings (CPHI) is currently at 65.41, the 7-day stands at 78.81, and the 3-day is sitting at 94.30.Many professionals agree that realizing a loss is just as important as picking a winner, so I've also included a potential loss area to point out my opinion of when to abort mission. Price Target is anywhere form 0.60 to 0.72 by mid week. The stock has returned 21.95% weekly, which was maintained at 9.59% in the 1-month period. I'm looking forward to the upside of that return!
AMEX:CPHIShort
by SoWaVvY